MRNA vs ZBH
Moderna vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | MRNA | ZBH |
|---|
| AI Score |
61
|
66
|
| Price |
$158.81
|
$100.18
|
| P/E Ratio |
-17.40×
|
24.45×
|
| ROE |
-32.6%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
-12.6%
|
69.9%
|
| Debt / Equity |
0.19×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
68.6
|
62.6
|
| Beta |
0.899
|
0.462
|
| Expected Upside |
—
|
+0.5%
|
AI Committee View
Current Innellis committee reasoning for MRNA versus ZBH.
ZBH leads by 5 points.
ZBH scores 66/100 (Buy) versus MRNA at 61/100 (Buy).
MRNA Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 194.9% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -39.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -27.6% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is price-to-book of 1.4x is a discount to asset value. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical